Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Approximate complex electrical potential distribution in the monodomain model with unequal conductivity and relative permittivity anisotropy ratios.

Kwon H, de Morentin MM, Nagy JA, Rutkove SB, Sanchez B.

Physiol Meas. 2019 Sep 3;40(8):085008. doi: 10.1088/1361-6579/ab3aa1.

PMID:
31408853
2.

Permittivity of ex vivo healthy and diseased murine skeletal muscle from 10 kHz to 1 MHz.

Nagy JA, DiDonato CJ, Rutkove SB, Sanchez B.

Sci Data. 2019 Apr 18;6(1):37. doi: 10.1038/s41597-019-0045-2.

3.

New electrical impedance methods for the in situ measurement of the complex permittivity of anisotropic skeletal muscle using multipolar needles.

Kwon H, Guasch M, Nagy JA, Rutkove SB, Sanchez B.

Sci Rep. 2019 Feb 28;9(1):3145. doi: 10.1038/s41598-019-39277-0.

4.

Estimating Myofiber Size With Electrical Impedance Myography: a Study In Amyotrophic Lateral Sclerosis MICE.

Kapur K, Nagy JA, Taylor RS, Sanchez B, Rutkove SB.

Muscle Nerve. 2018 Nov;58(5):713-717. doi: 10.1002/mus.26187. Epub 2018 Sep 2.

PMID:
30175407
5.

Electrical impedance myography as a biomarker of myostatin inhibition with ActRIIB-mFc: a study in wild-type mice.

Nagy JA, Kapur K, Taylor RS, Sanchez B, Rutkove SB.

Future Sci OA. 2018 Apr 16;4(6):FSO308. doi: 10.4155/fsoa-2018-0002. eCollection 2018 Jul.

6.

A novel partial gravity ground-based analog for rats via quadrupedal unloading.

Mortreux M, Nagy JA, Ko FC, Bouxsein ML, Rutkove SB.

J Appl Physiol (1985). 2018 Jul 1;125(1):175-182. doi: 10.1152/japplphysiol.01083.2017. Epub 2018 Mar 22.

7.

Predicting myofiber size with electrical impedance myography: A study in immature mice.

Kapur K, Taylor RS, Qi K, Nagy JA, Li J, Sanchez B, Rutkove SB.

Muscle Nerve. 2018 Feb 24. doi: 10.1002/mus.26111. [Epub ahead of print]

8.

Electrical impedance myography detects age-related muscle change in mice.

Arnold WD, Taylor RS, Li J, Nagy JA, Sanchez B, Rutkove SB.

PLoS One. 2017 Oct 19;12(10):e0185614. doi: 10.1371/journal.pone.0185614. eCollection 2017.

9.

New electrical impedance methods for the in situ measurement of the complex permittivity of anisotropic biological tissues.

Kwon H, Nagy JA, Taylor R, Rutkove SB, Sanchez B.

Phys Med Biol. 2017 Nov 1;62(22):8616-8633. doi: 10.1088/1361-6560/aa8c95.

PMID:
28905814
10.

Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels.

Sitohy B, Chang S, Sciuto TE, Masse E, Shen M, Kang PM, Jaminet SC, Benjamin LE, Bhatt RS, Dvorak AM, Nagy JA, Dvorak HF.

Am J Pathol. 2017 Oct;187(10):2337-2347. doi: 10.1016/j.ajpath.2017.06.010. Epub 2017 Jul 21.

11.

Stromal-Based Signatures for the Classification of Gastric Cancer.

Uhlik MT, Liu J, Falcon BL, Iyer S, Stewart J, Celikkaya H, O'Mahony M, Sevinsky C, Lowes C, Douglass L, Jeffries C, Bodenmiller D, Chintharlapalli S, Fischl A, Gerald D, Xue Q, Lee JY, Santamaria-Pang A, Al-Kofahi Y, Sui Y, Desai K, Doman T, Aggarwal A, Carter JH, Pytowski B, Jaminet SC, Ginty F, Nasir A, Nagy JA, Dvorak HF, Benjamin LE.

Cancer Res. 2016 May 1;76(9):2573-86. doi: 10.1158/0008-5472.CAN-16-0022.

12.

The Effect of a Liner on the Dispersion of Sacral Interface Pressures During Spinal Immobilization.

Nemunaitis G, Roach MJ, Boulet M, Nagy JA, Kaufman B, Mejia M, Hefzy MS.

Assist Technol. 2015 Spring;27(1):9-17. doi: 10.1080/10400435.2014.940473.

PMID:
26132220
13.

PGC-1α induces SPP1 to activate macrophages and orchestrate functional angiogenesis in skeletal muscle.

Rowe GC, Raghuram S, Jang C, Nagy JA, Patten IS, Goyal A, Chan MC, Liu LX, Jiang A, Spokes KC, Beeler D, Dvorak H, Aird WC, Arany Z.

Circ Res. 2014 Aug 15;115(5):504-17. doi: 10.1161/CIRCRESAHA.115.303829. Epub 2014 Jul 9.

14.

RhoB controls coordination of adult angiogenesis and lymphangiogenesis following injury by regulating VEZF1-mediated transcription.

Gerald D, Adini I, Shechter S, Perruzzi C, Varnau J, Hopkins B, Kazerounian S, Kurschat P, Blachon S, Khedkar S, Bagchi M, Sherris D, Prendergast GC, Klagsbrun M, Stuhlmann H, Rigby AC, Nagy JA, Benjamin LE.

Nat Commun. 2013;4:2824. doi: 10.1038/ncomms3824.

15.

Home range size variation in female arctic grizzly bears relative to reproductive status and resource availability.

Edwards MA, Derocher AE, Nagy JA.

PLoS One. 2013 Jul 3;8(7):e68130. doi: 10.1371/journal.pone.0068130. Print 2013.

16.

Preventive health care among community-dwelling persons with spinal cord injury.

Roach MJ, Nagy JA, Mejia M, Nemunaitis G.

PM R. 2013 Jun;5(6):496-502. doi: 10.1016/j.pmrj.2012.11.004. Epub 2013 Jan 10.

PMID:
23313038
17.

Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets.

Nagy JA, Dvorak HF.

Clin Exp Metastasis. 2012 Oct;29(7):657-62. doi: 10.1007/s10585-012-9500-6. Epub 2012 Jun 13.

18.

Anti-VEGF/VEGFR therapy for cancer: reassessing the target.

Sitohy B, Nagy JA, Dvorak HF.

Cancer Res. 2012 Apr 15;72(8):1909-14. doi: 10.1158/0008-5472.CAN-11-3406. Review.

19.

Vascular hyperpermeability, angiogenesis, and stroma generation.

Nagy JA, Dvorak AM, Dvorak HF.

Cold Spring Harb Perspect Med. 2012 Feb;2(2):a006544. doi: 10.1101/cshperspect.a006544. Review.

20.

Subpopulation structure of caribou (Rangifer tarandus L.) in arctic and subarctic Canada.

Nagy JA, Johnson DL, Larter NC, Campbell MW, Derocher AE, Kelly A, Dumond M, Allaire D, Croft B.

Ecol Appl. 2011 Sep;21(6):2334-48.

PMID:
21939065
21.

Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy.

Sitohy B, Nagy JA, Jaminet SC, Dvorak HF.

Cancer Res. 2011 Nov 15;71(22):7021-8. doi: 10.1158/0008-5472.CAN-11-1693. Epub 2011 Sep 21.

22.

RhoJ is an endothelial cell-restricted Rho GTPase that mediates vascular morphogenesis and is regulated by the transcription factor ERG.

Yuan L, Sacharidou A, Stratman AN, Le Bras A, Zwiers PJ, Spokes K, Bhasin M, Shih SC, Nagy JA, Molema G, Aird WC, Davis GE, Oettgen P.

Blood. 2011 Jul 28;118(4):1145-53. doi: 10.1182/blood-2010-10-315275. Epub 2011 May 31.

23.

Proteolytic cleavage of versican and involvement of ADAMTS-1 in VEGF-A/VPF-induced pathological angiogenesis.

Fu Y, Nagy JA, Brown LF, Shih SC, Johnson PY, Chan CK, Dvorak HF, Wight TN.

J Histochem Cytochem. 2011 May;59(5):463-73. doi: 10.1369/0022155411401748. Epub 2011 Mar 16.

24.

Fast carnivores and slow herbivores: differential foraging strategies among grizzly bears in the Canadian Arctic.

Edwards MA, Derocher AE, Hobson KA, Branigan M, Nagy JA.

Oecologia. 2011 Apr;165(4):877-89. doi: 10.1007/s00442-010-1869-9. Epub 2010 Dec 12.

PMID:
21153738
25.

Moderation of calpain activity promotes neovascular integration and lumen formation during VEGF-induced pathological angiogenesis.

Hoang MV, Nagy JA, Fox JE, Senger DR.

PLoS One. 2010 Oct 25;5(10):e13612. doi: 10.1371/journal.pone.0013612.

26.

Active Rac1 improves pathologic VEGF neovessel architecture and reduces vascular leak: mechanistic similarities with angiopoietin-1.

Hoang MV, Nagy JA, Senger DR.

Blood. 2011 Feb 3;117(5):1751-60. doi: 10.1182/blood-2010-05-286831. Epub 2010 Oct 28.

27.

Cdc42-mediated inhibition of GSK-3β improves angio-architecture and lumen formation during VEGF-driven pathological angiogenesis.

Hoang MV, Nagy JA, Senger DR.

Microvasc Res. 2011 Jan;81(1):34-43. doi: 10.1016/j.mvr.2010.09.001. Epub 2010 Sep 16.

28.

Heterogeneity of the tumor vasculature.

Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF.

Semin Thromb Hemost. 2010 Apr;36(3):321-31. doi: 10.1055/s-0030-1253454. Epub 2010 May 20. Review.

29.

A descriptive study on vitamin D levels in individuals with spinal cord injury in an acute inpatient rehabilitation setting.

Nemunaitis GA, Mejia M, Nagy JA, Johnson T, Chae J, Roach MJ.

PM R. 2010 Mar;2(3):202-8; quiz 228. doi: 10.1016/j.pmrj.2010.01.010.

PMID:
20359685
30.

Vascular permeability and pathological angiogenesis in caveolin-1-null mice.

Chang SH, Feng D, Nagy JA, Sciuto TE, Dvorak AM, Dvorak HF.

Am J Pathol. 2009 Oct;175(4):1768-76. doi: 10.2353/ajpath.2009.090171. Epub 2009 Sep 3.

31.

Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level.

Zhang X, Kazerounian S, Duquette M, Perruzzi C, Nagy JA, Dvorak HF, Parangi S, Lawler J.

FASEB J. 2009 Oct;23(10):3368-76. doi: 10.1096/fj.09-131649. Epub 2009 Jun 15.

32.

Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase.

Xue Q, Nagy JA, Manseau EJ, Phung TL, Dvorak HF, Benjamin LE.

Arterioscler Thromb Vasc Biol. 2009 Aug;29(8):1172-8. doi: 10.1161/ATVBAHA.109.185918. Epub 2009 May 14.

33.

VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation.

Chang SH, Kanasaki K, Gocheva V, Blum G, Harper J, Moses MA, Shih SC, Nagy JA, Joyce J, Bogyo M, Kalluri R, Dvorak HF.

Cancer Res. 2009 May 15;69(10):4537-44. doi: 10.1158/0008-5472.CAN-08-4539. Epub 2009 May 12.

34.

The L6 protein TM4SF1 is critical for endothelial cell function and tumor angiogenesis.

Shih SC, Zukauskas A, Li D, Liu G, Ang LH, Nagy JA, Brown LF, Dvorak HF.

Cancer Res. 2009 Apr 15;69(8):3272-7. doi: 10.1158/0008-5472.CAN-08-4886. Epub 2009 Apr 7.

35.

Why are tumour blood vessels abnormal and why is it important to know?

Nagy JA, Chang SH, Dvorak AM, Dvorak HF.

Br J Cancer. 2009 Mar 24;100(6):865-9. doi: 10.1038/sj.bjc.6604929. Epub 2009 Feb 24. Review.

36.

Chapter 3. The adenoviral vector angiogenesis/lymphangiogenesis assay.

Nagy JA, Shih SC, Wong WH, Dvorak AM, Dvorak HF.

Methods Enzymol. 2008;444:43-64. doi: 10.1016/S0076-6879(08)02803-6.

PMID:
19007660
37.

Vascular permeability, vascular hyperpermeability and angiogenesis.

Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF.

Angiogenesis. 2008;11(2):109-19. doi: 10.1007/s10456-008-9099-z. Epub 2008 Feb 22. Review.

38.

VEGF-A and the induction of pathological angiogenesis.

Nagy JA, Dvorak AM, Dvorak HF.

Annu Rev Pathol. 2007;2:251-75. Review.

PMID:
18039100
39.

Historical and ecological determinants of genetic structure in arctic canids.

Carmichael LE, Krizan J, Nagy JA, Fuglei E, Dumond M, Johnson D, Veitch A, Berteaux D, Strobeck C.

Mol Ecol. 2007 Aug;16(16):3466-83.

PMID:
17688546
40.

Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting.

Wirzenius M, Tammela T, Uutela M, He Y, Odorisio T, Zambruno G, Nagy JA, Dvorak HF, Ylä-Herttuala S, Shibuya M, Alitalo K.

J Exp Med. 2007 Jun 11;204(6):1431-40. Epub 2007 May 29.

41.

Potential spatial overlap of heritage sites and protected areas in a boreal region of northern Canada.

Leroux SJ, Schmiegelow FK, Nagy JA.

Conserv Biol. 2007 Apr;21(2):376-86.

PMID:
17391188
42.

Down syndrome candidate region 1 isoform 1 mediates angiogenesis through the calcineurin-NFAT pathway.

Qin L, Zhao D, Liu X, Nagy JA, Hoang MV, Brown LF, Dvorak HF, Zeng H.

Mol Cancer Res. 2006 Nov;4(11):811-20.

43.

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.

Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, Sun J, Monahan-Earley RA, Shiojima I, Nagy JA, Lin MI, Walsh K, Dvorak AM, Briscoe DM, Neeman M, Sessa WC, Dvorak HF, Benjamin LE.

Cancer Cell. 2006 Aug;10(2):159-70.

44.

Permeability properties of tumor surrogate blood vessels induced by VEGF-A.

Nagy JA, Feng D, Vasile E, Wong WH, Shih SC, Dvorak AM, Dvorak HF.

Lab Invest. 2006 Aug;86(8):767-80. Epub 2006 May 29.

45.

Orphan nuclear receptor TR3/Nur77 regulates VEGF-A-induced angiogenesis through its transcriptional activity.

Zeng H, Qin L, Zhao D, Tan X, Manseau EJ, Van Hoang M, Senger DR, Brown LF, Nagy JA, Dvorak HF.

J Exp Med. 2006 Mar 20;203(3):719-29. Epub 2006 Mar 6.

46.

VEGF-A, cytoskeletal dynamics, and the pathological vascular phenotype.

Nagy JA, Senger DR.

Exp Cell Res. 2006 Mar 10;312(5):538-48. Epub 2005 Nov 28. Review.

PMID:
16310771
47.

Antiangiogenic properties of gold nanoparticles.

Mukherjee P, Bhattacharya R, Wang P, Wang L, Basu S, Nagy JA, Atala A, Mukhopadhyay D, Soker S.

Clin Cancer Res. 2005 May 1;11(9):3530-4.

48.

Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin.

Satchi-Fainaro R, Mamluk R, Wang L, Short SM, Nagy JA, Feng D, Dvorak AM, Dvorak HF, Puder M, Mukhopadhyay D, Folkman J.

Cancer Cell. 2005 Mar;7(3):251-61.

49.

Ultrastructural localization of platelet endothelial cell adhesion molecule (PECAM-1, CD31) in vascular endothelium.

Feng D, Nagy JA, Pyne K, Dvorak HF, Dvorak AM.

J Histochem Cytochem. 2004 Jan;52(1):87-101.

PMID:
14688220
50.

Copper status of muskoxen: a comparison of wild and captive populations.

Barboza PS, Rombach EP, Blake JE, Nagy JA.

J Wildl Dis. 2003 Jul;39(3):610-9.

PMID:
14567223

Supplemental Content

Support Center